Org 28611: Difference between revisions

| verifiedrevid = 451603454

| image = Org28611_structure.png

| routes_of_administration =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number =

| molecular_weight = 383.526 g/mol

'''Org 28611''' ('''SCH-900,111''') is a drug developed by [[Organon International]] which acts as a potent [[cannabinoid]] [[Receptor (biochemistry)|receptor]] [[full agonist]] at both the [[Cannabinoid receptor 1|CB₁]] and [[Cannabinoid receptor 2|CB₂]] receptors. It was developed with the aim of finding a [[solubility|water soluble]] cannabinoid agonist suitable for [[intravenous]] use as an [[analgesic]],<ref>{{Cite doi|10.1039/c0md00022a}}</ref> and while it achieved this aim and has progressed as far as Phase II [[clinical trial]]s in humans as both a [[sedative]] and an [[analgesic]], results against the comparison drugs ([[midazolam]] and [[morphine]] respectively) were not particularly favourable in initial testing.<ref name="pmid18635703">{{cite journal |author=Zuurman L, Passier PC, de Kam M, Kleijn HJ, Cohen AF, van Gerven JM |title=Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers |journal=Journal of Psychopharmacology (Oxford, England) |volume=23 |issue=6 |pages=633–44 |year=2009 |month=August |pmid=18635703 |doi=10.1177/0269881108091551 |url=}}</ref><ref>[http://clinicaltrials.gov/ct2/show/NCT00782951 A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery]</ref>

* [[Org 28312]]